Harbour BioMed
Weiwei Chen has extensive work experience spanning several industries and roles. Weiwei is currently a Senior Advisor at KKR Asia Limited, where they provide expertise and guidance. Prior to this, Chen served as an Independent Non-Executive Director at LianBio, an Independent Non-Executive Director at DFI Retail Group, and held various positions at HARBOUR BIOMED, including Non-Executive Director and Senior Business Advisor. Weiwei also served as the Board Senior Advisor at PHARMPLUS, a KKR invested company. Before transitioning into advisory roles, Chen had notable positions in the corporate world. Weiwei was the Vice President and Chief Financial Officer at Starbucks (China) and the Chief Financial Officer for the China Division of Yum! Brands. Chen also held senior financial positions at Sanofi and Schering-Plough, where they served as the Chief Financial Officer for the Asia region and China, respectively. Weiwei started their career as a Senior Auditor at Ernst & Young. Chen's diverse experience across corporate finance, leadership, and advisory roles has equipped him with a solid foundation in strategic decision-making and financial management.
Weiwei Chen has a Bachelor of Science (BS) degree in Accounting from the University of Illinois Urbana-Champaign. Additionally, Weiwei holds a Master of Business Administration (MBA) degree from Rutgers University.
This person is not in any teams
This person is not in any offices
Harbour BioMed
1 followers
Harbour BioMed is an Immune-Driven Global Bio-therapeutics Company discovering, developing and delivering Innovative Therapeutics for Oncology and Immunology. The company's discovery and development programs are centered around its two patented transgenic mouse platforms for human antibody discovery - the H2L2 and the HCAb.